PMC:7556165 / 26690-27243 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-sample-MedDRA

{"project":"LitCovid-sample-MedDRA","denotations":[{"id":"T65","span":{"begin":161,"end":174},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"},{"id":"T66","span":{"begin":253,"end":256},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"}],"attributes":[{"id":"A66","pred":"meddra_id","subj":"T66","obj":"http://purl.bioontology.org/ontology/MEDDRA/10050289"},{"id":"A65","pred":"meddra_id","subj":"T65","obj":"http://purl.bioontology.org/ontology/MEDDRA/10002484"}],"text":"As a matter of fact, ACE2 displays its carboxypeptidase activity converting Ang-II to a heptapeptide, namely Ang1–7 (Turner et al., 2004). ACE2 can also convert angiotensin I (Ang-I) to the non apeptide Ang1–9, which is in turn converted into Ang1–7 by ACE, competing with Ang-I and thus further decreasing Ang-II (Arendse et al., 2019; Figure 3). Ang1–7 has been demonstrated to bind to the MasR receptor, which was initially regarded as an orphan receptor, since the use of a MasR antagonist caused inhibition of Ang1–7 effects (Alenina et al., 2008)."}

LitCovid-sample-CHEBI

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T94","span":{"begin":161,"end":174},"obj":"Chemical"}],"attributes":[{"id":"A94","pred":"chebi_id","subj":"T94","obj":"http://purl.obolibrary.org/obo/CHEBI_147350"},{"id":"A95","pred":"chebi_id","subj":"T94","obj":"http://purl.obolibrary.org/obo/CHEBI_2718"}],"text":"As a matter of fact, ACE2 displays its carboxypeptidase activity converting Ang-II to a heptapeptide, namely Ang1–7 (Turner et al., 2004). ACE2 can also convert angiotensin I (Ang-I) to the non apeptide Ang1–9, which is in turn converted into Ang1–7 by ACE, competing with Ang-I and thus further decreasing Ang-II (Arendse et al., 2019; Figure 3). Ang1–7 has been demonstrated to bind to the MasR receptor, which was initially regarded as an orphan receptor, since the use of a MasR antagonist caused inhibition of Ang1–7 effects (Alenina et al., 2008)."}

LitCovid-sample-sentences

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T170","span":{"begin":0,"end":138},"obj":"Sentence"},{"id":"T171","span":{"begin":139,"end":347},"obj":"Sentence"},{"id":"T172","span":{"begin":348,"end":553},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"As a matter of fact, ACE2 displays its carboxypeptidase activity converting Ang-II to a heptapeptide, namely Ang1–7 (Turner et al., 2004). ACE2 can also convert angiotensin I (Ang-I) to the non apeptide Ang1–9, which is in turn converted into Ang1–7 by ACE, competing with Ang-I and thus further decreasing Ang-II (Arendse et al., 2019; Figure 3). Ang1–7 has been demonstrated to bind to the MasR receptor, which was initially regarded as an orphan receptor, since the use of a MasR antagonist caused inhibition of Ang1–7 effects (Alenina et al., 2008)."}

LitCovid-sample-Pubtator

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"705","span":{"begin":21,"end":25},"obj":"Gene"},{"id":"706","span":{"begin":139,"end":143},"obj":"Gene"},{"id":"707","span":{"begin":253,"end":256},"obj":"Gene"},{"id":"708","span":{"begin":478,"end":482},"obj":"Gene"},{"id":"709","span":{"begin":392,"end":396},"obj":"Gene"}],"attributes":[{"id":"A706","pred":"pubann:denotes","subj":"706","obj":"Gene:59272"},{"id":"A705","pred":"pubann:denotes","subj":"705","obj":"Gene:59272"},{"id":"A708","pred":"pubann:denotes","subj":"708","obj":"Gene:116511"},{"id":"A707","pred":"pubann:denotes","subj":"707","obj":"Gene:1636"},{"id":"A709","pred":"pubann:denotes","subj":"709","obj":"Gene:116511"}],"text":"As a matter of fact, ACE2 displays its carboxypeptidase activity converting Ang-II to a heptapeptide, namely Ang1–7 (Turner et al., 2004). ACE2 can also convert angiotensin I (Ang-I) to the non apeptide Ang1–9, which is in turn converted into Ang1–7 by ACE, competing with Ang-I and thus further decreasing Ang-II (Arendse et al., 2019; Figure 3). Ang1–7 has been demonstrated to bind to the MasR receptor, which was initially regarded as an orphan receptor, since the use of a MasR antagonist caused inhibition of Ang1–7 effects (Alenina et al., 2008)."}

LitCovid-sample-UniProt

LitCovid-sample-PD-GO-BP-0

{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T68","span":{"begin":39,"end":64},"obj":"http://purl.obolibrary.org/obo/GO_0004180"}],"text":"As a matter of fact, ACE2 displays its carboxypeptidase activity converting Ang-II to a heptapeptide, namely Ang1–7 (Turner et al., 2004). ACE2 can also convert angiotensin I (Ang-I) to the non apeptide Ang1–9, which is in turn converted into Ang1–7 by ACE, competing with Ang-I and thus further decreasing Ang-II (Arendse et al., 2019; Figure 3). Ang1–7 has been demonstrated to bind to the MasR receptor, which was initially regarded as an orphan receptor, since the use of a MasR antagonist caused inhibition of Ang1–7 effects (Alenina et al., 2008)."}

LitCovid-sample-GO-BP

{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T70","span":{"begin":39,"end":64},"obj":"http://purl.obolibrary.org/obo/GO_0004180"}],"text":"As a matter of fact, ACE2 displays its carboxypeptidase activity converting Ang-II to a heptapeptide, namely Ang1–7 (Turner et al., 2004). ACE2 can also convert angiotensin I (Ang-I) to the non apeptide Ang1–9, which is in turn converted into Ang1–7 by ACE, competing with Ang-I and thus further decreasing Ang-II (Arendse et al., 2019; Figure 3). Ang1–7 has been demonstrated to bind to the MasR receptor, which was initially regarded as an orphan receptor, since the use of a MasR antagonist caused inhibition of Ang1–7 effects (Alenina et al., 2008)."}

LitCovid-PubTator

{"project":"LitCovid-PubTator","denotations":[{"id":"705","span":{"begin":21,"end":25},"obj":"Gene"},{"id":"706","span":{"begin":139,"end":143},"obj":"Gene"},{"id":"707","span":{"begin":253,"end":256},"obj":"Gene"},{"id":"708","span":{"begin":478,"end":482},"obj":"Gene"},{"id":"709","span":{"begin":392,"end":396},"obj":"Gene"}],"attributes":[{"id":"A705","pred":"tao:has_database_id","subj":"705","obj":"Gene:59272"},{"id":"A706","pred":"tao:has_database_id","subj":"706","obj":"Gene:59272"},{"id":"A707","pred":"tao:has_database_id","subj":"707","obj":"Gene:1636"},{"id":"A708","pred":"tao:has_database_id","subj":"708","obj":"Gene:116511"},{"id":"A709","pred":"tao:has_database_id","subj":"709","obj":"Gene:116511"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"As a matter of fact, ACE2 displays its carboxypeptidase activity converting Ang-II to a heptapeptide, namely Ang1–7 (Turner et al., 2004). ACE2 can also convert angiotensin I (Ang-I) to the non apeptide Ang1–9, which is in turn converted into Ang1–7 by ACE, competing with Ang-I and thus further decreasing Ang-II (Arendse et al., 2019; Figure 3). Ang1–7 has been demonstrated to bind to the MasR receptor, which was initially regarded as an orphan receptor, since the use of a MasR antagonist caused inhibition of Ang1–7 effects (Alenina et al., 2008)."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T170","span":{"begin":0,"end":138},"obj":"Sentence"},{"id":"T171","span":{"begin":139,"end":347},"obj":"Sentence"},{"id":"T172","span":{"begin":348,"end":553},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"As a matter of fact, ACE2 displays its carboxypeptidase activity converting Ang-II to a heptapeptide, namely Ang1–7 (Turner et al., 2004). ACE2 can also convert angiotensin I (Ang-I) to the non apeptide Ang1–9, which is in turn converted into Ang1–7 by ACE, competing with Ang-I and thus further decreasing Ang-II (Arendse et al., 2019; Figure 3). Ang1–7 has been demonstrated to bind to the MasR receptor, which was initially regarded as an orphan receptor, since the use of a MasR antagonist caused inhibition of Ang1–7 effects (Alenina et al., 2008)."}

PMC:7556165 / 26690-27243 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7556165 / 26690-27243 JSON TXT